ArticleBMC public health2025
Global, regional, and national burden of hypertension-induced cardiorenal disease, 1990-2021 and projections to 2050: a systematic analysis for the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrating Chair Yoga and Manual Therapy Into Hypertension Management: Effects on Autonomic Regulation, Muscle Viscoelasticity, and Mental Well-Being.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- Predictors of Medication Adherence Among Taiwanese Community-Based Adults with Hypertension: The Application of Temporal Self-Regulation Theory.Behavioral sciences (Basel, Switzerland) · 2026Article
- Association between the cumulative average triglyceride glucose-BMI and hypertension incidence among the middle-aged and older population: a prospective nationwide cohort study in China.Journal of hypertension · 2026Article
- Does the blood pressure response to renal denervation depend on the degree of sympathetic overactivity?Journal of hypertension · 2026Article
- Monocyte-mediated mechanisms in idiopathic pulmonary fibrosis: opportunities for early intervention.Apoptosis : an international journal on programmed cell death · 2026Review
- Global, regional, and national burden of pulmonary arterial hypertension in adults aged ≥60 years from 1990-2021: SDI-stratified trend analysis and projections to 2050.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo explore the impact of hypertension-induced cardiorenal disease on disability rates and mortality, this study reported the burden of cardiorenal disease caused by hypertension (including hypertensive heart disease [HHD] and hypertensive kidney disease) between 1990 and 2021.
methodsUtilizing data from the Global Burden of Disease (GBD) database, this study delivered a comprehensive analysis of the burden of hypertension-induced cardiorenal disease. Hypertension was estimated in terms of disability-adjusted life years (DALYs) and mortality, age-standardized death rates (ASDRs), and age-standardized DALY rates (ASRs), considering age, gender, geographical distribution, socio-demographic index (SDI), and cardiorenal disease. Additionally, the estimated annual percentage change (EAPC) was calculated to assess trends in ASDRs and ASRs from 1990 to 2021.
resultsIn comparison with 1990, the mortality and DALYs of hypertension-induced cardiorenal disease rose in 2021, resulting in 1,332,099 deaths and 25,462,184 DALYs of HHD, as well as 454,358 deaths and 10,850,728 DALYs of chronic kidney disease(CKD). Between 1990 and 2021, the ASDRs and ASRs of hypertensive heart disease decreased by 21.99%(95% UI, -31.92-6.74%) and 25.81%(95% U, -34.45- -10.07%), respectively. In contrast, the ASDRs and ASRs of hypertension-attributable CKD decreased by 29.21%(95%UI, 11.55-39.65%) and 19.15%(95% UI, 4.31-27.76%), respectively. In 2021, the highest ASDR and ASR of HHD were recorded in Central Sub-Saharan Africa and Southern Sub-Saharan Africa, while those of hypertension-attributable CKD peaked in Western Sub-Saharan Africa and Southeast Asia. Projections indicate a continued decline in HHD ASDRs through 2050, whereas hypertension-attributable CKD is expected to exhibit an upward trend over the same period.
conclusionDespite the declining mortality rate of HHD, the increasing incidence of hypertension-induced CKD underscores that hypertension-attributable cardiovascular and kidney diseases remain a globally urgent public health concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.